motor function

UK-240455是一种有效的且具有选择性的 N-甲基 D-天冬氨酸 (NMDA) 甘氨酸受体拮抗剂，具有神经保护作用和改善帕金森病模型的运动的功能，是治疗帕金森病的潜在候选化合物。

Golexanolone (Golexanolona) 是一种新的 GABA-A 受体调节类固醇拮抗剂，可减少外周炎症和神经炎症，并改善慢性高氨血症大鼠的认知和运动功能，可用于研究肝性脑病。

Gastrin-Releasing Peptide, human(TFA） (93755-85-2 free base) 是一种调节性人类肽，可引发胃泌素释放并调节胃酸分泌和肠道运动功能。支配胃G 细胞的迷走神经节后纤维释放GRP，刺激G 细胞释放胃泌素。

exo-Tetrahydrocannabivarin (Compound 12) 是一种Δ9,11-THC类似物。它能够以相对较低的结合力结合大麻素受体 (CB) (IC50: 1.4 μM)。此外，exo-Tetrahydrocannabivarin 在小鼠中展示出运动和镇痛活性。

Nrf2 activator 19 是一种能穿透血脑屏障的NRF2/HO-1激活剂，显现出强大的抗氧化和神经保护作用。它能够有效减轻脑损伤并减少Reactive Oxygen Species (ROS) 的积累，抑制神经元的凋亡 (apoptosis)，促进神经功能和运动能力的恢复。此外，Nrf2 activator 19 在缺血性脑卒中研究中展现出显著的研究前景。

A-86929 是一种强效且选择性的多巴胺D1受体激动剂，pKi值为7.3。在6-OHDA诱导的单侧黑质损伤的大鼠模型中，A-86929 可显著诱导旋转行为，并在MPTP诱导的帕金森病狨猴模型中改善运动功能。此外，它在减少可卡因诱导的大鼠渴求行为及改善Haloperidol导致的恒河猴认知缺陷上展现出潜力。A-86929 可用于神经疾病研究。

MCOPPB is a potent and selective agonist for the nociceptin receptor with a pKi of 10.07, much weaker activity at other opioid receptors. In animal studies, MCOPPB produces potent anxiolytic effects, with no inhibition of motor or memory function, and onl

SKF 81297 hydrobromide 是一种选择性的多巴胺 D1 类受体激动剂，对 D1 和 D5 受体亚型具有高亲和力，Ki 值为 1.9 nM。SKF 81297盐酸盐在体内表现出中枢活性并广泛用于研究多巴胺系统的神经调节作用，尤其是在认知功能和运动活动相关的研究中，如帕金森病。

Crisdesalazine (AAD 2004) 是微粒体前列腺素 E2 合酶 1 (mPGES-1) 的抑制剂。 Crisdesalazine 可减少自噬体形成、轴索病变和运动神经元变性，改善运动功能并延长寿命。

Rg3039 (PF-06687859) 是一种具有口服活性、能够透过血脑屏障的DcpS 抑制剂，其IC50=0.069 nM。

Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I.1 Mouse urocortin II shares 34 and 42% sequence homology with rat CRF and urocortin . It is expressed in mouse paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and in motor nuclei of the brainstem and spinal ventral horn. Urocortin II selectively binds to CRF1 over CRF2 receptors (Kis = 0.66 and >100 nM, respectively) and induces cAMP production in CHO cells expressing CRF2 (EC50 = 0.14 nM). In vivo, urocortin II suppresses nighttime food intake by 35% in rats when administered intracerebroventricularly at a dose of 1 μg. Urocortin II (0.1 and 0.5 μg, i.c.v) stimulates fecal pellet output, increases distal colonic transit, and inhibits gastric emptying in mice.2References1. Reyes, T.M., Lewis, K., Perrin, M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98(5), 2843-2848 (2001).2. Martinez, V., Wang, L., Million, M., et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25(10), 1733-1744 (2004). Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I.1 Mouse urocortin II shares 34 and 42% sequence homology with rat CRF and urocortin . It is expressed in mouse paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and in motor nuclei of the brainstem and spinal ventral horn. Urocortin II selectively binds to CRF1 over CRF2 receptors (Kis = 0.66 and >100 nM, respectively) and induces cAMP production in CHO cells expressing CRF2 (EC50 = 0.14 nM). In vivo, urocortin II suppresses nighttime food intake by 35% in rats when administered intracerebroventricularly at a dose of 1 μg. Urocortin II (0.1 and 0.5 μg, i.c.v) stimulates fecal pellet output, increases distal colonic transit, and inhibits gastric emptying in mice.2 References1. Reyes, T.M., Lewis, K., Perrin, M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98(5), 2843-2848 (2001).2. Martinez, V., Wang, L., Million, M., et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25(10), 1733-1744 (2004).

Domperidone (R33812) monomaleate 是选择性的、口服具有活力的多巴胺-2 受体 (dopamine-2 receptor) 拮抗剂。Domperidone monomaleate 能够影响胃和小肠的化学感受器触发区和运动功能，具有止吐和促动力剂作用。

PBT434 is a novel, brain-penetrant, small molecule inhibitor of α-synuclein aggregation. In transgenic animal models of Parkinson disease (A53T) and MSA (PLP-α-Syn), PBT434 reduced α-synuclein aggregation, preserved neurons and improved motor function. Glial cell inclusions were also reduced in a murine MSA model. PBT434 is thought to act by redistributing reactive iron across membranes, thereby blocking intracellular protein aggregation and oxidative stress. The affinity of PBT434 for iron is greater than that of α-synuclein but lower than that of iron trafficking proteins, e.g., ferritin.

NNZ 2591为环状甘氨酸脯氨酸(cGP)小肽的合成类似物，具有口服活性，能穿过血脑屏障。在缺血性脑损伤模型中展现出神经保护作用，并改善帕金森病大鼠模型的运动功能，有望用于研究缺血性脑损伤和天使综合征。

hNTS1R agonist-1 (Compound 10)为能穿透血脑屏障的hNTS1R全激动剂（Ki：6.9 nM）。它能提升帕金森病（PD）模型小鼠的运动能力及记忆。作为一种Neurotensin(8-13)类似物，hNTS1R agonist-1同时具有神经保护作用。

Tat-CIRP是一种肽类抑制剂，用于抑制髓样分化2蛋白(MD-2，亦称淋巴细胞抗原96 [LY96])与寒冷诱导的RNA结合蛋白(CIRP)之间的蛋白-蛋白相互作用。它通过与MD-2结合，干扰MD-2与CIRP之间的相互作用，这一作用在共免疫沉淀实验中得到证实。在体内实验中，Tat-CIRP (10及20 mg/kg) 能够减少由中脑动脉闭塞(MCAO)引发的小鼠脑梗死体积。同样，在通过血栓引发脑梗死的恒河猴模型中，Tat-CIRP同样能减少脑梗死体积，并缩短患中风一侧手臂抓取并放下食物的时间。

Gastrin-Releasing Peptide, human is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate the G cells of the stomach release GRP, which stimulates the G cells to release gastrin.

Sumanirole maleate (PNU-95666E)是一种D2受体完全激动剂，具有高选择性的特点（ED50 ＝46 nM），能够改善帕金森病患者的运动功能并且在不宁腿综合征的研究中发挥重要作用。